Riversand Named a Leader in Gartner Magic Quadrant for Master Data Management (MDM) Solutions
Riversand, a leading cloud-native SaaS Master Data Management (MDM) and Product Information Management (PIM) solution provider, today announced that it has been named a Leader in the Gartner 2021 Magic Quadrant for Master Data Management (MDM) Solutions* report.
Riversand’s customers include the world’s biggest brands in retail, food and consumer-packaged goods (CPG), manufacturing, transportation and distribution, and energy. Within the Leader quadrant of the report, Riversand is the only pure play cloud-native SaaS platform.
“For nearly twenty years, we’ve been honored to have worked with phenomenal clients and deliver better data experiences to their customers and partners,” said Upen Varanasi, CEO and co-founder of Riversand. “We believe our ability to show business value for our clients has been recognized by Gartner and being named a Leader in this 2021 Magic Quadrant for MDM Solutions report. We are thrilled to see our long-term vision paying off.”
Riversand had previously been named a Visionary consecutively in four previous Gartner Magic Quadrant reports.
“Proving and providing strong business value guided by a smart strategy – it’s what our clients expect from Riversand,” said Varanasi. “We will continue to invest ahead of the curve and help ensure that our clients continue to get the most forward-thinking master data management solutions available.”
Download the full Gartner Magic Quadrant report here*: https://riversand.me/GartnerMDMMQ21_PR
*Gartner, “Magic Quadrant for Master Data Management Solutions,” Simon Walker, Sally Parker, Malcolm Hawker, Divya Radhakrishnan, Alan Dayley, 27 January 2021
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, express or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About Riversand
Riversand provides a Master Data Experience Platform (MDxP), enabling customers to leverage their data through intelligent insights, automation, and multi-domain SaaS solutions. Riversand’s MDxP platform is the engine that powers customers’ digital transformation journeys through improved business agility, faster adoption and improved collaboration across the enterprise. Driving data to experiences and insights, Riversand has a vision of helping companies know their customers better, move products faster, automate processes, mitigate risk and run their businesses smarter. Visit Riversand for more information and follow us @RiversandMDM on Twitter and Riversand on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005934/en/
Contact information
Riversand PR
Ilana Friedman
pr@riversand.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Novotech Issues White Paper to Help Sponsors Strengthen Early-Phase Oncology Strategy and Execution15.12.2025 15:05:00 EET | Press release
Novotech, a leading global full-service clinical research organization (CRO) and scientific advisory company, has released a new white paper, Early-Phase Oncology – Clinical Research Landscape and CRO Enablers (2025), offering in-depth analysis of the key drivers shaping early-phase oncology development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215843975/en/ With approximately 60% of oncology agents progressing from Phase I to Phase II, but only 3–6% reaching regulatory approval, the paper outlines the factors influencing early-stage success, including trial design, patient selection, and regional development pathways. The paper highlights Australia’s continued position as a global first-in-human (FIH) and early-phase research hub. Its ethics-led review frameworks, which can support trial initiation within roughly 4–8 weeks, combined with established FIH centers, oncology networks, and cost efficiencies, position Au
Ant Group Announces Major Upgrades to Its 15-Million-MAU AI Health App AQ Amid Wider Push into Health Sector15.12.2025 15:03:00 EET | Press release
Ant Group today announced major upgrades to its AI health app AQ, with a new Chinese name “Ant A-Fu.” The character “Fu” conveys good wishes and well-being, reflecting the app’s goal to promote better health and quality of life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215203213/en/ Ant Group’s AI health app AQ features three core capabilities: health Q&A, AI health companion, and integrated health services. The upgraded version of AQ now features three core capabilities: health Q&A, AI health companion, and integrated health services. Launched in June 2025, AQ has rapidly grown to 15 million monthly active users, making it China’s leading AI health management app. Positioned as an AI health companion service, AQ currently answers over 5 million health-related questions every day. The announcement comes amid China’s ongoing demographic shift. According to projections from the National Health Commission, by around 20
Copeland and Daikin Cooperation Brings Solutions to European Customers15.12.2025 15:00:00 EET | Press release
Copeland and Daikin, two global leaders in heating, ventilation and air conditioning (HVAC) solutions, today announced the expansion of their existing joint venture into Europe. Through this cooperation, the companies will introduce advanced inverter swing rotary compressors, power electronics and controls designed specifically for European residential heat pumps. This collaboration underscores both companies’ commitment to accelerate the energy transition, with heat pumps recognized by industry reports as a cornerstone technology helping to reduce global carbon dioxide emissions by an estimated 500 million tons by 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215625806/en/ (Left to right) Ross B. Shuster, CEO of Copeland and Jiro Tomita, executive associate officer of Daikin As Europe rapidly transitions away from fossil fuels, the demand for residential heat pumps is growing in parallel with ambitious sustainabil
Visa Unveils New Global Stablecoins Advisory Practice15.12.2025 14:00:00 EET | Press release
Visa (NYSE: V), a global leader in digital payments, today announced the launch of its Stablecoins Advisory Practice. The new value-added service offering by Visa Consulting & Analytics (VCA) provides actionable insights and recommendations to guide banks, fintechs, merchants, and businesses of all sizes on market fit, strategy, and implementation. As the stablecoin market cap surpasses $250 billion, Visa’s settlement volume has accelerated, reaching a $3.5 billion annualized run rate as of November 30. Businesses are turning to Visa’s new Stablecoins Advisory Practice to unlock growth opportunities. “Putting our members first has always been our mission, and we’re committed to exploring innovations that strengthen financial health and convenience for those we serve. Stablecoins may represent an opportunity to enhance speed and lower cost in payments, so with the support of Visa, we are evaluating how this technology could fit into our broader strategy to deliver meaningful value to ou
SK Capital Announces Definitive Agreement to Invest in Swixx BioPharma AG to Drive the Next Phase of Growth and Global Expansion15.12.2025 13:30:00 EET | Press release
SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the life sciences, specialty materials, and ingredients sectors, today announced that its affiliate has reached an agreement to invest in Swixx BioPharma AG (“Swixx” or the “Company”) to accelerate the Company’s next phase of growth and global expansion. The investment values the Company in excess of EUR €1.5 billion. Swixx is the global leader in rest-of-world pharmaceutical commercialization services dedicated to delivering innovative, life-saving medications to underserved and hard-to-reach markets. Stuart Swanson and Petr Němec, Swixx’s Co-Founders, and Jean-Michel Lespinasse and Petr Pipal, Swixx’s CEO and CFO, respectively, will all retain significant ownership stakes in Swixx as part of the transaction. Existing institutional investors HBM Healthcare Investments, a Swiss-listed investment company for the global healthcare market, and Mérieux Equity Partners, a leading healthcare-specializ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom